Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 4:24 AM ET


Company Overview of Akebia Therapeutics, Inc.

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, an oral therapy which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients, as well as tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

245 First Street

Suite 1100

Cambridge, MA 02142

United States

Founded in 2007

41 Employees





Key Executives for Akebia Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $552.3K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 47
Total Annual Compensation: $415.9K
Chief Medical Officer and Senior Vice President
Age: 62
Total Annual Compensation: $181.5K
Compensation as of Fiscal Year 2014.

Akebia Therapeutics, Inc. Key Developments

Akebia Therapeutics, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:30 AM

Akebia Therapeutics, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:30 AM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States. Speakers: John P. Butler, Chief Executive Officer, President and Director.

Akebia Therapeutics To Sell Its Stock

Akebia Therapeutics, Inc. (NasdaqGM:AKBA) is looking to sell $75 million in stock.

Akebia Therapeutics Inc. Initiates Phase 3 PRO2TECT™ Program

Akebia Therapeutics Inc. announced several corporate and clinical developments consistent with its objectives for 2015, including dosing the first patient in its global Phase 3 PRO2TECT program in December. This program is evaluating vadadustat (formerly AKB-6548) in non-dialysis patients with anemia related to chronic kidney disease (NDD-CKD). In addition, the U.S. Food and Drug Administration (FDA) recently opened Akebia's Investigational New Drug (IND) application, allowing the company to initiate a Phase 1 clinical study of AKB-6899, an orally-available HIF stabilizer, in oncology. The company also made progress with its intellectual property efforts in Japan for vadadustat. The PRO2TECT Phase 3 program includes two separate studies that will collectively enroll approximately 3,100 NDD-CKD patients across 500 sites globally. The first patient was recently dosed in the PRO2TECT correction study, which is enrolling anemic patients not currently being treated with recombinant erythropoiesis stimulating agents (rESAs). The PRO2TECT conversion study includes patients currently receiving rESA who will be converted to either vadadustat or the active control with the goal of maintaining their baseline hemoglobin levels. Both studies include a 1:1 randomization and an open label, active-control, non-inferiority design. Primary endpoints include an efficacy assessment of the hemoglobin response and cardiovascular safety as measured by major adverse cardiovascular events. The PRO2TECT program is designed to support registration in major markets worldwide and to collect the data required to establish a new standard of care for chronic kidney disease (CKD) patients. The company expects to complete enrollment in late 2017.

Similar Private Companies By Industry

Company Name Region
Scholar Rock, Inc. United States
Plexigen, Inc. United States
Galenea Corp. United States
Mx Biodevices, LLC United States
Encoded Genomics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Akebia Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at